Combining the weight loss-inducing drugs with those that aim to build muscle mass has quickly become a priority for companies like Regeneron Pharmaceuticals and Eli Lilly, Bloomberg reported Jan. 10.
“There will be the drugs that get there first, and there will be the drugs that actually are the best. If you can address things such as tolerability or the muscle loss…you’ll see there will be room for drugs that actually do it better than the first generation,” Teresa Graham, CEO of Roche Pharmaceuticals, a company also working on a solution, told the Journal.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.